Introduction {#s1}
============

Alzheimer's disease (AD) is the most common age-related form of dementia (Alzheimer's Association, [@B1]). The etiopathogenesis of the disease is still unknown, and AD is defined as a multifactorial pathology whose development and progression is the result of the combination of several factors (Carreiras et al., [@B7]). People with a cognitive decline which is more severe than expected, but without the pathological failure typical of AD, are diagnosed as being affected by mild cognitive impairment (MCI; Petersen, [@B33]; Forlenza et al., [@B13]).

Recent results suggested the involvment of synaptosomal-associated protein 25 (SNAP-25), a component of the soluble *N*-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex involved in the exocytotic release of neurotransmitters during synaptic transmission (Antonucci et al., [@B2]), in neurological disorders, including AD (Noor and Zahid, [@B29]). Thus, it was shown that: (1) SNAP-25 protein expression is reduced in brains (Shimohama et al., [@B35]; Greber et al., [@B17]; Musunuri et al., [@B28]), and increased in cerebrospinal fluid (Brinkmalm et al., [@B5]; Sutphen et al., [@B36]) of AD patients compared to elderly healthy subjects; (2) the *SNAP-25* single nucleotide polymorphism (SNP) rs363050 is associated with alterations of categorical fluency and a reduced localized brain activity in AD patients (Guerini et al., [@B19]), and was shown to be predictive of a worst outcome in AD patients undergoing rehabilitative therapy (Guerini et al., [@B20]); (3) the overexpression of SNAP-25 in the rat adult dorsal hippocampus leads to the deregulation of memory consolidation (McKee et al., [@B26]); and (4) the overexpression of SNAP-25 in rat hippocampal neuron culture cells is associated with synaptic transmission disorders (Owe-Larsson et al., [@B30]).

MicroRNAs (miRNAs) are short non-coding RNAs (containing about 20--24 nucleotides) involved in mRNA silencing and post-transcriptional regulation of gene expression (Bartel, [@B3]) *via* their ability to bind the 3′untranslated region (3′UTR). miRNAs are thus key players in the normal function of cells, and impairments in their modulation, regulation and/or expression are associated with pathologies including tumors (Castro et al., [@B8]; Drusco and Croce, [@B11]; Elghoroury et al., [@B12]; Koutsaki et al., [@B21]; Mansoori et al., [@B25]), stroke (Vijayan and Reddy, [@B37]) and type 2 diabetes mellitus (Liang et al., [@B23]). A possible role for miRNAs alterations has been postulated in AD (Provost, [@B34]; Delay et al., [@B10]; Pan et al., [@B31]; Kumar et al., [@B22]; Wang et al., [@B39]). In the present pilot study, we verified whether serum concentration of the miRNAs that bind the 3′UTR region of *SNAP-25* differs when AD, MCI and healthy controls (HCs) individuals are compared and, if this was the case, whether the expression of these miRNAs is modulated by the *SNAP-25* rs363050 polymorphism.

Materials and Methods {#s2}
=====================

Patients and Controls {#s2-1}
---------------------

The Discovery Cohort was formed by 12 elderly HCs who had already been genotyped for rs363050 *SNAP-25* (Guerini et al., [@B20]); six of them were homozygous for the G allele and six for the A allele.

For the Study Cohort 22 patients affected by AD and 22 individuals with a diagnosis of MCI were recruited by the Department of Neurorehabilitation of IRCCS Santa Maria Nascente, Don Carlo Gnocchi Foundation---ONLUS, Milan, Italy. Patients were diagnosed either with AD according to the NINCDS-ADRDA Work Group criteria (McKhann et al., [@B27]) or with MCI according to Petersen (Petersen, [@B32]) and Grundman operation criteria (Grundman et al., [@B18]). To exclude reversible cases of dementia, all patients underwent complete medical and neurological examination, laboratory analyses, and magnetic resonance imaging (MRI) or computed tomography (CT) scan. Twenty-two HCs matched with patients for gender and age were also enrolled in the study. All these 66 subjects (22 AD, 22 MCI and 22 HCs) had already been genotypized for rs363050 *SNAP-25* (Guerini et al., [@B20]), and were selected because they carried either the A or G homozygous allele for rs363050. No other complications, including malnutrition, vitamin deficiency syndromes or tumor pathologies, were present in any of the individuals enrolled in the study. Blood count, urine analysis, blood chemistry screen, serum folate, B12 levels, and thyroid function tests were normal in all the subjects.

This study was carried out in accordance with the recommendations of ethics committee of the Fondazione Don Carlo Gnocchi with written informed consent from all subjects, or their relatives when appropriate. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the ethics committee of the Fondazione Don Carlo Gnocchi.

For the methodologies regarding *in silico* selection of miRNAs targeting *SNAP-25* 3′UTR, isolation of miRNAs from human serum samples, screening profile and validation of miRNAs targeting 3′UTR *SNAP-25*, genotyping, and statistical analysis, see [Supplementary Material](#SM1){ref-type="supplementary-material"}.

Results {#s3}
=======

Serum miRNAs Profiling: Discovery Cohort {#s3-1}
----------------------------------------

Expression profile of 90 miRNAs targeting and putatively binding 3′UTR of *SNAP-25* that were selected by *in silico* analysis and are known to be expressed in serum was performed in all the individuals part of the Discovery Cohort (12 HCs; six rs363050 AA genotype vs. six rs363050 GG genotype). Fifty-seven of the 90 miRNAs were detected in serum. Serum relative concentration of six miRNAs was identified as being differentially modulated by the *SNAP-25* rs363050 genotype, as their expression ratio was \>2.5-fold or \<−2.5-fold in both software used (qbase and Qiagen Software): miR-181a-5p, miR-130a-3p, miR-15b-3p, miR27b-3p, miR-361-5p and miR-23a-3p; all these miRNAs were up regulated in GG genotype compared to AA genotype HC.

Serum miRNAs Expression Validation: Study Cohort {#s3-2}
------------------------------------------------

Results were subsequently validated with single qPCR in a larger population (Study Cohort) that included AD, MCI and HC individuals ([Table 1](#T1){ref-type="table"}).

###### 

Demographic, clinical data and laboratory findings of the study cohort.

                              AD patients           MCI subjects            Healthy controls
  --------------------------- --------------------- ----------------------- ---------------------
  **N**                       22                    22                      22
  **Gender (M:F)**            6:16                  11:11                   9:13
  **Age, years**              78.00; 74.00--81.50   76.00; 72.00--80.00     70.00; 61.25--85.25
  **MMSE**                    22.15; 18.90--24.30   24.70; 22.63--27.68\*   --
  **ApoE ε-4 carriers (%)**   48                    18                      18
  **miR-27b-3p (%)**          91                    100                     95
  fold median; IQR            1.33; 0.35--3.70      1.74; 0.57--2.59        1.43; 0.40--2.29
  **miR-130a-3p (%)**         36                    55                      36
  fold median; IQR            0.79; 0.08--3.14      1.25; 0.24--2.68        1.04; 0.14--1.94
  **miR-15b-3p (%)**          14                    32                      18
  fold median; IQR            0.95; 0.48--1.82      0.82; 0.34--1.76        0.77; 0.49--2.54
  **miR-23a-3p (%)**          100                   100                     100
  fold median; IQR            0.90; 0.20--3.39      1.32; 0.49--1.99        0.95; 0.44--2.81
  **miR-181a-5p (%)**         65^\#^                95                      77
  fold median; IQR            1.90; 1.20--3.20      1.64; 0.80--4.33        0.96; 0.62--1.89
  **miR-361--3p (%)**         59                    100                     77
  fold median; IQR            0.75; 0.23--5.72      1.25; 0.77--2.43        1.05; 0.55--4.35

*Data are reported as median and interquartile range. AD, Alzheimer's disease; MCI, mild cognitive impairment; M, male; F, female; MMSE, mini mental state evaluation; ApoE, apolipoprotein E; IQR, interquartile range. \**p* = 0.01 between AD and MCI subjects. ^\#^*p* = 0.02 between AD and MCI subjects*.

miR-23a-3p was detected in all individuals whereas miR-15b-3p was observed only in few cases (AD: 14%; MCI: 32%; HCs: 18%). miR-181a-5p, was statistically more frequent in MCI (95%) compared to AD patients (65%; *p* = 0.02), whereas HCs had an intermediate frequency (77%). Frequency and fold expression of each miRNA is summarized in [Table 1](#T1){ref-type="table"}.

GG homozygous rs363050 genotype AD patients (ADGG) were characterized by a lower expression of miR-27b-3p, miR-23a-3p and miR181a-5p compared to HCs, regardless of the rs363050 genotypes, as well as to all other groups.

In particular, ADGG were characterized by a significantly lower miR-27b-3p expression (0.23; 0.08--0.71), compared to in AA homozygous AD (ADAA; 2.23; 0.79--3.84; *p* = 0.02) and MCI individuals (MCIAA; 1.63; 0.89--2.89; *p* = 0.03; [Figure 1A](#F1){ref-type="fig"}).

![miR-27b-3p **(A)**, miR-23a-3p **(B)** and miR-181a-5p **(C)** expression fold (Log~10~ transformed) in serum of Alzheimer's disease (AD) patients, mild cognitive impairment (MCI) individuals and healthy controls (HCs) splitted forsynaptosomal-associated protein of 25 kDa (*SNAP-25*) rs363050 genotype. ADAA, AA homozygous AD patients; ADGG, GG homozygous AD patients; MCIAA, AA homozygous MCI individuals; MCIGG, GG homozygous MCI individuals; HCAA, AA homozygous HCs; HCGG, GG homozygous HCs.](fnagi-11-00052-g0001){#F1}

Moreover, miR-23a-3p expression reduced as well in ADGG (0.27; 0.05--0.29) compared to all the other groups; this reduction reached statistical significance in comparison with AA homozygous HCs (HCAA; 0.97; 0.56--2.23; *p* = 0.02), ADAA (1.03; 0.30--3.65; *p* = 0.05), MCIAA (1.04; 0.39--1.42; *p* = 0.03), and GG homozygous MCI individuals (MCIGG; 2.14; 0.38--1.01; *p* = 0.03; [Figure 1B](#F1){ref-type="fig"}).

Finally, miR-181a-5p expression was lower in ADGG (0.17; 0.02--1.56) compared to all the other groups (vs. ADAA: 2.33; 1.27--2.87; *p* = 0.05; [Figure 1C](#F1){ref-type="fig"}). Overall results of miRNAs expression considering the rs363050 genotype are summarized in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. No differences were found in relation with sex, apolipoprotein E (*ApoE*) genotype or mini mental state evaluation (MMSE) score.

Discussion {#s4}
==========

AD is a neurodegenerative disorder in which the rate of decline and functional restoration depend on the capacity for neural plasticity within residual neural tissues (Goldberg et al., [@B16]); this is at least partially influenced by polymorphisms in genes involved in synaptic transmission, including *SNAP-25* (Guerini et al., [@B19], [@B20]). In particular, the rs363050 SNP of *SNAP-25* was shown to correlate with brain activity (Guerini et al., [@B19]) and the outcome of rehabilitation (Guerini et al., [@B20]) in AD patients.

By binding the 3′UTR region of genes, miRNAs inhibit the translation of mRNA into proteins, thus modulating gene expression (Cai et al., [@B6]). All the miRNAs analyzed in the present work putatively target and modulate *SNAP-25* expression, although miR-27a/b alone has so far been shown to inhibit the activity of *SNAP-25* (Machitani et al., [@B24]). Herein, we describe that the serum expression of miR-27b-3p, miR-23a-3p and miR-181a-5p is significantly reduced in AD patients that are homozygous for the G allele in the rs363050 SNP of *SNAP-25*. Although it is expressed in an intronic region, rs363050 was shown to modulate the expression of SNAP-25 protein; GG homozygosity, in particular, results in a reduced production of the protein compared to the AA homozygosis (Braida et al., [@B4]). Importantly, three independent studies detected a very low expression of SNAP-25 protein in the brain of AD patients compared to those of elderly not-AD individuals (Shimohama et al., [@B35]; Greber et al., [@B17]; Musunuri et al., [@B28]). Interestingly, miRNAs miR-27b-3p, miR-23a-3p and miR-181a-5p were also recently shown to be deregulated in serum of patients that underwent ischemic stroke (Wu et al., [@B40]; Cheng et al., [@B9]; Vijayan et al., [@B38]).

Based on these results it is tempting to speculate that in rs363050 GG homozygous AD patients, in whom SNAP-25 protein expression is reduced because of their genetic background, lower amounts of miRNAs that down regulate SNAP-25 expression would be an attempt to bypass such reduced SNAP-25 levels. In MCI individuals this phenomenon is not present possibly because modulation of miRNA expression only characterizes the later phases of dementia.

It is important to note that, as SNAP-25 is more expressed in excitatory neurons than in inhibitory neurons (Frassoni et al., [@B14]; Garbelli et al., [@B15]), these miRNAs could have neuroprotective properties; this possibility needs to be analyzed more in-depth.

It is nevertheless important to underline that we analyzed miRNAs expression in serum alone; these data might not reflect what goes on intracellularly, where miRNA-mRNA interactions, and the consequent modulation of gene expression take place. For these reasons our results need to be validated in a larger cohort, including also rs363050 heterozygous subjects, in which intracellular miRNA expression will need to be investigated. Finally, further experiment based on luciferase assay will be necessary to confirm the interaction between the miRNAs and SNAP-25 3′ UTR region and the effects of such interaction on SNAP-25 expression.

In conclusion, results of this pilot study, although preliminary and requiring to be confirmed by other independent studies with larger cohorts, suggest that the interaction between genetic and epigenetic factors modulate SNAP-25 expression and could contribute to the alterations in synaptic functionality, activity, neuro-plasticity observed in AD.
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